Michael S. Kim MD, Melissa R. Romoff BA, Ryan Beyer MD, Emily Tse BA, Hao-Hua Wu MD, Don Y. Park MD, Yu-Po Lee MD, Nitin Bhatia MD, Sohaib Hashmi MD, Emily S. Mills
{"title":"Cefazolin prophylaxis is associated with lower surgical site infection risk than vancomycin following elective spine surgery","authors":"Michael S. Kim MD, Melissa R. Romoff BA, Ryan Beyer MD, Emily Tse BA, Hao-Hua Wu MD, Don Y. Park MD, Yu-Po Lee MD, Nitin Bhatia MD, Sohaib Hashmi MD, Emily S. Mills","doi":"10.1016/j.xnsj.2026.100857","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Surgical site infection (SSI) remains a major cause of morbidity following elective spine surgery, with incidence rates up to 3%. Current guidelines recommend cefazolin as the first-line prophylactic antibiotic due to its efficacy against methicillin-sensitive <em>Staphylococcus aureus</em> (MSSA) and coagulase-negative staphylococci (CoNS). However, reported B-lactam allergies are commonly cited in clinical practice as a reason for substitution with vancomycin, which provides inferior coverage for MSSA and limited gram-negative activity. Prior single center studies suggest higher SSI risk with vancomycin, but large-scale evidence remains limited.</div></div><div><h3>Methods</h3><div>A retrospective cohort analysis was conducted using the TriNetX US Collaborative Network (2015-2023). Adults undergoing elective spine surgery, including transforaminal or posterior interbody fusion (TLIF/PLIF), multilevel lumbar fusion, posterior cervical fusion, anterior cervical discectomy and fusions (ACDF), and microdiscectomy, were identified. Patients receiving perioperative cefazolin or vancomycin within 24 hours of surgery were included. 1:1 propensity score matching controlled for demographics, comorbidities, and infection risk factors. The primary outcome was 90-day SSI, assessed using ICD-10 diagnosis codes. Risk ratios (RR) were estimated using Cox proportional hazards models.</div></div><div><h3>Results</h3><div>After matching, 12,996 patients were included across 5 procedure cohorts. Cefazolin prophylaxis was associated with lower or comparable SSI risk compared with vancomycin across all procedures. Statistically significant differences were observed for TLIF/PLIF (0.82% vs. 2.30%; RR 0.36, 95% CI 0.18–0.7; p = .0019) and microdiscectomy (0.34% vs. 0.69%; RR 0.50, 95% CI 0.27–0.93; p = .025). Nonsignificant trends favored cefazolin for posterior cervical fusion (0.88% vs. 1.41%), multilevel lumbar fusion (1.25% vs. 1.51%), and ACDF (0.30% vs. 0.54%).</div></div><div><h3>Conclusions</h3><div>Cefazolin prophylaxis is associated with significantly lower SSI risk in elective spine procedures. These findings support cefazolin as the preferred perioperative antibiotic and emphasize the need for accurate B-lactam allergy assessment to optimize infection prevention and antimicrobial stewardship in spine surgery.</div></div>","PeriodicalId":34622,"journal":{"name":"North American Spine Society Journal","volume":"25 ","pages":"Article 100857"},"PeriodicalIF":3.2000,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"North American Spine Society Journal","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666548426000119","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/2/8 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Surgical site infection (SSI) remains a major cause of morbidity following elective spine surgery, with incidence rates up to 3%. Current guidelines recommend cefazolin as the first-line prophylactic antibiotic due to its efficacy against methicillin-sensitive Staphylococcus aureus (MSSA) and coagulase-negative staphylococci (CoNS). However, reported B-lactam allergies are commonly cited in clinical practice as a reason for substitution with vancomycin, which provides inferior coverage for MSSA and limited gram-negative activity. Prior single center studies suggest higher SSI risk with vancomycin, but large-scale evidence remains limited.
Methods
A retrospective cohort analysis was conducted using the TriNetX US Collaborative Network (2015-2023). Adults undergoing elective spine surgery, including transforaminal or posterior interbody fusion (TLIF/PLIF), multilevel lumbar fusion, posterior cervical fusion, anterior cervical discectomy and fusions (ACDF), and microdiscectomy, were identified. Patients receiving perioperative cefazolin or vancomycin within 24 hours of surgery were included. 1:1 propensity score matching controlled for demographics, comorbidities, and infection risk factors. The primary outcome was 90-day SSI, assessed using ICD-10 diagnosis codes. Risk ratios (RR) were estimated using Cox proportional hazards models.
Results
After matching, 12,996 patients were included across 5 procedure cohorts. Cefazolin prophylaxis was associated with lower or comparable SSI risk compared with vancomycin across all procedures. Statistically significant differences were observed for TLIF/PLIF (0.82% vs. 2.30%; RR 0.36, 95% CI 0.18–0.7; p = .0019) and microdiscectomy (0.34% vs. 0.69%; RR 0.50, 95% CI 0.27–0.93; p = .025). Nonsignificant trends favored cefazolin for posterior cervical fusion (0.88% vs. 1.41%), multilevel lumbar fusion (1.25% vs. 1.51%), and ACDF (0.30% vs. 0.54%).
Conclusions
Cefazolin prophylaxis is associated with significantly lower SSI risk in elective spine procedures. These findings support cefazolin as the preferred perioperative antibiotic and emphasize the need for accurate B-lactam allergy assessment to optimize infection prevention and antimicrobial stewardship in spine surgery.
手术部位感染(SSI)仍然是择期脊柱手术后发病的主要原因,发生率高达3%。目前的指南推荐头孢唑林作为一线预防性抗生素,因为它对甲氧西林敏感的金黄色葡萄球菌(MSSA)和凝固酶阴性葡萄球菌(con)有效。然而,在临床实践中,报告的b -内酰胺过敏通常被引用为万古霉素替代的原因,万古霉素对MSSA的覆盖范围较低,革兰氏阴性活性有限。先前的单中心研究表明万古霉素有较高的SSI风险,但大规模证据仍然有限。方法采用TriNetX美国协作网络(2015-2023)进行回顾性队列分析。接受选择性脊柱手术的成人,包括经椎间孔或后路椎间融合术(TLIF/PLIF)、多节段腰椎融合术、颈椎后路融合术、颈椎前路椎间盘切除术和融合术(ACDF)以及微椎间盘切除术。纳入围手术期24小时内接受头孢唑林或万古霉素治疗的患者。1:1倾向评分匹配控制了人口统计学、合并症和感染危险因素。主要终点为90天SSI,使用ICD-10诊断代码进行评估。采用Cox比例风险模型估计风险比(RR)。结果匹配后,12996例患者被纳入5个手术队列。在所有程序中,与万古霉素相比,头孢唑林预防与较低或相当的SSI风险相关。TLIF/PLIF的差异有统计学意义(0.82% vs. 2.30%; RR 0.36, 95% CI 0.18-0.7; p = 0.0019)和微椎间盘切除术(0.34% vs. 0.69%; RR 0.50, 95% CI 0.27-0.93; p = 0.025)。头孢唑林在颈椎后路融合(0.88% vs. 1.41%)、腰椎多节段融合(1.25% vs. 1.51%)和ACDF (0.30% vs. 0.54%)中的应用趋势不显著。结论:选择性脊柱手术中,头孢唑林预防可显著降低SSI风险。这些发现支持头孢唑林作为围手术期首选抗生素,并强调需要准确的b -内酰胺过敏评估,以优化脊柱外科感染预防和抗菌药物管理。